Cagrilintide is a long-acting analog of the pancreatic hormone amylin, developed by Novo Nordisk through fatty acid acylation to enable once-weekly subcutaneous dosing
Each vial contains approximately 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV, for a total of 80 mg of combined peptide content
Piteau S, Olver A, Kim SJ et al (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat
Good candidates include: Adults recovering from soft-tissue injuries such as tendon strains, ligament sprains, or muscle pulls
Moreover, this treatment supports kidney and liver functions while aiding the detoxification process, thereby improving your overall well-being